Compare 6- vs 9-month treatment for tuberculous meningitis
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This Phase 2 study tests whether a shorter, stronger 6-month set of medicines works as well as the usual 9-month regimen for tuberculous meningitis (TB infection in the covering of the brain/spinal cord). The goal is to improve outcomes while reducing treatment time and exposure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have TB meningitis confirmed as definite, probable, or possible by routine medical testing done within the last 21 days.
- You must be able to take the full standard TB treatment plan that your clinical team recommends for TB meningitis.
- Recent blood test results must be within certain safety limits (kidney function, anemia level, white blood cell count, platelets, and liver/bilirubin levels within set ranges).
- You likely need a recent pregnancy test if you could become pregnant, and you must use reliable contraception during treatment and for 30 days after stopping.
- You must not have taken more than 14 total days of certain first-line TB medicines in the last 90 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a shorter, more intensive treatment for tuberculosis that affects the brain. It may help reduce side effects while still curing the infection.
This trial tests if giving a stronger combination of TB drugs for meningitis can save more lives. It's for patients who have been diagnosed with tuberculosis meningitis and have not yet started more than 5 days of TB treatment.
This study tests whether a shorter course of TB treatment (4 months) works just as well as the standard longer course (6 months) for people whose chest X-ray suggests TB but whose sputum test does not confirm it. It aims to reduce treatment burden while keeping the cure rate high.
This study tests a shorter six-month treatment for tuberculosis that is resistant to rifampicin, a common antibiotic. The goal is to make treatment easier and possibly safer while still being effective.
This study tests a 6-month treatment with four oral medicines (bedaquiline, delamanid, linezolid, and levofloxacin) for people whose TB is resistant to rifampin. The goal is to see if this all-pill combination is safe and effective in treating this difficult type of TB.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
Hear when a new Tuberculous Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.